Cellectar Biosciences Return on Equity

Cellectar Biosciences (CLRB) currently reports a ROE of -74.73%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Cellectar Biosciences's ROE history and peer comparisons.

Cellectar Biosciences's ROE of -74.73% is lower than the Healthcare sector average of 22.01%. That is roughly 439.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cellectar Biosciences's current -74.73% should be judged against Healthcare norms (sector average: 22.01%) and against CLRB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -74.73%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Cellectar Biosciences, and consider following CLRB for alerts when major investors trade the stock.

Cellectar Biosciences is classified in the Healthcare sector. On ROE, it currently shows -74.73% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLRB with unrelated industries.